Cardiovascular Intervention Improvement Telemedicine Study

Hypertension Clinical Trial

Official title:

Cardiovascular Intervention Improvement Telemedicine Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01142908
• Other study ID #: IIR 08-297
• Secondary ID: 08-297
• Status: Completed
• Phase: N/A
• Start date: November 1, 2011
• Est. completion date: May 22, 2015

Study information

• Verified date: July 2023
• Source: VA Office of Research and Development
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cardiovascular disease (CVD) is the leading cause of death in the United States; more than 80% of veterans have > 2 risk factors for CVD. Our study is one of the first to examine the implementation of a tailored behavioral/educational self-management intervention in primary care clinics designed to improve CVD risk. The proposed study could result in a leap forward in CVD risk management among veterans for several reasons: 1) ) This is a novel extension of our previous interventions that have demonstrated improved BP, now designed to address multiple chronic conditions contributing to CVD risk, particularly hyperlipidemia and diabetes. The study focuses on both multiple CVD-related risk factor management and medication management 2) The intervention is multi-behavioral; it addresses patients' various health behavior (e.g., smoking, diet, and medication adherence). 3) Components of the intervention will include specific recommendations and transportability of intervention application software and tracking packages that will allow clinic managers to implement the intervention if it is effective.

Description:

Anticipated Impacts on Veteran's Healthcare: Cardiovascular disease (CVD) is the leading cause of death in the U.S.; more than 80% of veterans have > 2 risk factors for CVD. An intervention that addresses multiple CVD risk factors among high-risk veterans has the greatest potential to improve morbidity and mortality.

Project Background/Rationale: The proposed study will take place in two VA primary care clinics (1-Community-Based Outpatient Clinics and 1-primary care clinic affiliated with a hospital). We will improve CVD risk among veterans by addressing the modifiable risk factors of systolic blood pressure (SBP), smoking, and low-density lipoprotein cholesterol (LDL-C). The intervention will be tailored to the needs of vulnerable high risk patients (e.g. African Americans, low literate) and integrated into clinics, thereby enhancing the potential for benefit and generalizability to other settings.

The proposed study could significantly improve CVD risk management among veterans for several reasons: 1) This intervention is a novel extension of our previous efficacious interventions, but provides a novel extension to address multiple chronic conditions contributing to CVD risk. 2) The intervention focuses on both multiple CVD-related behaviors and medication management. 3) The intervention was developed to ensure implementation across a large and representative sample of veterans; and; 4) The intervention, if found efficacious and financially self-sustaining, could be widely implemented within the VA healthcare system.

Project Objectives: The proposed study will examine two research questions:

1. Can patients randomized to a clinical pharmacist-administered telephone behavioral/ medication management intervention tailored to their needs improve CVD outcomes relative to a control group over 12 months? Primary Hypothesis: (H1) Veterans who receive the behavioral/medication intervention will have greater improvement of their CVD Risk Profile over the 12 months of follow-up as compared to the control group.

Secondary Hypotheses: (H2) Veterans who receive the intervention will have improved medication adherence, physical activity, improved diet, lower body mass index as compared to the control group over 12 months of follow-up. (H3) Veterans who receive the intervention will have greater improvements in LDL over the 12 months of follow-up as compared to the control group. (H4) Veterans with diabetes who receive the intervention will have greater improved HbA1c as compared to the control group over 12 months of follow-up.

2. If the intervention is found to be effective, is it cost effective? Project Methods: To address these hypotheses, we propose a two-arm randomized clinical trial design in which 500 patients with cardiovascular disease will be randomized to either the education control group or the intervention group. Patients randomized to the intervention group will receive a clinical pharmacist-administered intervention, which focuses on behavioral and a medication management. The intervention will occur over 12 months. Patients randomized to the control group will receive educational material about CVD reduction. Given the national prevalence of CVD and the dismal rates of risk factor control, intensive, but easily disseminated interventions such as the one proposed could significantly improve treatment of this epidemic in the VA.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 428
• Est. completion date: May 22, 2015
• Est. primary completion date: April 30, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Enrolled in one of three Durham Veterans Affairs Medical Center (DVAMC) Primary Care Clinics affiliated with the hospital or the Raleigh Community-Based Outpatient Clinic (CBOC) for at least one year;

• At least one visit to a primary care physician (PCP) at the Raleigh CBOC or Durham Veterans Affairs Medical Center (VAMC) associated primary care clinics in the previous 12 months;

• Outpatient diagnostic code for hypertension and/or hypercholesterolemia and lab values indicating either poorly controlled BP levels (>150/90 Hg) AND/OR LDL (>130mg/dl) in the previous year.

Exclusion Criteria:

• diagnosed with metastatic cancer,

• diagnosed with dementia,

• active diagnosis of psychosis,

• treated with dialysis,

• most recent creatinine lab level >2.5 or no creatinine lab value within past year

• hospitalized for a stroke, heart attack, or had surgery for blocked arteries in the past 3 months,

• participating in another interventional trial,

• not currently receiving care at the Durham VAMC or the Raleigh CBOC

• resident of a nursing home,

• hard time seeing type/printing on books, magazines articles, etc.

• hard time hearing on the telephone

• limited/no access to telephone

• plans to move medical care from DVAMC or Raleigh CBOC in next 12 months

• CVD care is currently being managed by a clinical pharmacist

• HbA1C value in the last 90day > 10% and patient is currently not on an insulin regimen.

Related Conditions & MeSH terms

• Cardiovascular Disease
• Cardiovascular Diseases
• Diabetes
• Hyperlipidemia
• Hyperlipidemias
• Hyperlipoproteinemias
• Hypertension

Intervention

Behavioral:
• Pharmacist CVD
clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.

Locations

Country	Name	City	State
United States	Durham VA Medical Center, Durham, NC	Durham	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States, 

References & Publications (6)

Bosworth HB, Olsen MK, McCant F, Stechuchak KM, Danus S, Crowley MJ, Goldstein KM, Zullig LL, Oddone EZ. Telemedicine cardiovascular risk reduction in veterans: The CITIES trial. Am Heart J. 2018 May;199:122-129. doi: 10.1016/j.ahj.2018.02.002. Epub 2018 — View Citation

Goldstein KM, Oddone EZ, Bastian LA, Olsen MK, Batch BC, Washington DL. Characteristics and Health Care Preferences Associated with Cardiovascular Disease Risk among Women Veterans. Womens Health Issues. 2017 Nov-Dec;27(6):700-706. doi: 10.1016/j.whi.2017 — View Citation

Goldstein KM, Stechuchak KM, Zullig LL, Oddone EZ, Olsen MK, McCant FA, Bastian LA, Batch BC, Bosworth HB. Impact of Gender on Satisfaction and Confidence in Cholesterol Control Among Veterans at Risk for Cardiovascular Disease. J Womens Health (Larchmt). — View Citation

Melnyk SD, Zullig LL, McCant F, Danus S, Oddone E, Bastian L, Olsen M, Stechuchak KM, Edelman D, Rakley S, Morey M, Bosworth HB. Telemedicine cardiovascular risk reduction in veterans. Am Heart J. 2013 Apr;165(4):501-8. doi: 10.1016/j.ahj.2012.08.005. Epu — View Citation

Zullig LL, Melnyk SD, Stechuchak KM, McCant F, Danus S, Oddone E, Bastian L, Olsen M, Edelman D, Rakley S, Morey M, Bosworth HB. The Cardiovascular Intervention Improvement Telemedicine Study (CITIES): rationale for a tailored behavioral and educational p — View Citation

Zullig LL, Stechuchak KM, Goldstein KM, Olsen MK, McCant FM, Danus S, Crowley MJ, Oddone EZ, Bosworth HB. Patient-reported medication adherence barriers among patients with cardiovascular risk factors. J Manag Care Spec Pharm. 2015 Jun;21(6):479-85. doi: — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)	Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and VA Computerized Patient Record System (CPRS) data review). "New cases" of diabetes are allowed to be updated at 6 and 12 months f/u.	Baseline
Primary	Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)	Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and CPRS data review). "New cases" of diabetes are allowed to be updated at 6 and 12 months f/u.	6 months
Primary	Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)	Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and CPRS data review). "New cases" of diabetes are allowed to be updated at 6 and 12 months f/u.	12 months
Secondary	Mean Systolic Blood Pressure	Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews	Baseline
Secondary	Mean Systolic Blood Pressure	Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews	6 months
Secondary	Mean Systolic Blood Pressure	Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews	12 months
Secondary	Mean Diastolic Blood Pressure	Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews	Baseline
Secondary	Mean Diastolic Blood Pressure	Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews	6 months
Secondary	Mean Diastolic Blood Pressure	Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews	12 months
Secondary	Medication Non-adherence	First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.	Baseline
Secondary	Medication Non-adherence	First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.	6 months
Secondary	Medication Non-adherence	First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.	12 months
Secondary	Cholesterol LDL	Collected during interview visit by lab personnel	Baseline
Secondary	Cholesterol LDL	Collected during interview visit by lab personnel	6 months
Secondary	Cholesterol LDL	Collected during interview visit by lab personnel	12 months
Secondary	Body Mass Index	Calculated from vitals (height & weight) obtained during interview	Baseline
Secondary	Body Mass Index	Calculated from vitals (height & weight) obtained during interview	6 months
Secondary	Body Mass Index	Calculated from vitals (height & weight) obtained during interview	12 months
Secondary	HBA1C in Diabetic Patients	Lab values collected at interview visit by lab personnel	Baseline
Secondary	HBA1C in Diabetic Patients	Lab values collected at interview visit by lab personnel	6 months
Secondary	HBA1C in Diabetic Patients	Lab values collected at interview visit by lab personnel	12 months